IE 11 is not supported. For an optimal experience visit our site on another browser.

Aegerion Pharmaceuticals Announces Issuance of Patent for Treating Diseases Associated With Hyperlipidemia and Hypercholesterolemia Using Lomitapide

/ Source: GlobeNewswire

CAMBRIDGE, Mass., April 27, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today the issuance of Patent No. 7,932,268 for lomitapide for "Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects" by the United States Patent and Trademark Office.

The patent relates specifically to the treatment of hyperlipidemia or hypercholesterolemia, including severe hypercholesterolemia, using step-wise, increasing doses of lomitapide. Such dosing regimens are an essential component of Aegerion's development of lomitapide and other MTP inhibitors. The patent extends until August of 2027 and may be eligible for listing in the U.S. Food and Drug Administration Orange Book.  This patent application has been filed broadly in major markets, and is currently pending or issued in other jurisdictions.

"This is an important milestone for Aegerion," commented Marc D. Beer, Chief Executive Officer of Aegerion, "and we are most appreciative of Dr. Daniel Radar of the University of Pennsylvania, the inventor of the patent."  Mr. Beer continued, "This patent is an important addition to the Aegerion intellectual property portfolio as titrating the doses enables lomitapide to be used at maximum efficacy while maintaining the highest tolerability profile for the patient. It has the potential to extend patent protection on the use of lomitapide to August 2027."

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product, lomitapide, is in Phase III clinical development. Lomitapide is initially being developed to treat patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The Company also plans to initiate a clinical program for lomitapide to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia.  

Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Private Securities Litigation Reform Act of 1995, including statements regarding expected regulatory filings for and commercialization of the Company's lead product candidate, lomitapide. The forward-looking statements in this release do not constitute guarantees of future performance. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. The risks and uncertainties include, the Company's history of operating losses; the Company's potential need for additional capital to fund operations and develop its product candidates; uncertainties associated with the clinical development and associated regulatory filings of the Company's product candidates, including the risk that the Company's regulatory filings may not be accepted by the applicable regulatory authorities; the risk that the Company's product candidates may not be approved for any indication, or if approved; the risk that the finally approved definition of the targeted patient populations for the Company's product candidates may be narrower than expected; risks associated with undesirable side effects experienced by some patients in clinical trials for the Company's product candidates; risks associated with the Company's lack of sales and marketing experience; the highly competitive industry in which the Company operates; risks associated with the Company's intellectual property rights and the extent to which such intellectual property rights protect the Company's product candidates; the risk that third parties may allege that the Company infringes their intellectual property rights or that the Company has failed to comply with the provisions of its in-license agreements; risks associated with the Company's reliance on third parties, in particular clinical research organizations and contract manufacturers; risks associated with the Company's ability to recruit, hire and retain qualified personnel; and risks associated with volatility in the Company's stock price as a newly public company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by the Company, see the disclosure contained in the Company's public filings with the Securities and Exchange Commission, including the Company's recent Annual Report on Form 10-K under the heading "Risk Factors" and available on its investor relations website at and on the SEC's website at 

CONTACT: Aegerion Pharmaceuticals, Inc. Corporate Will Lewis, President +1 (908) 707-2100 LaVoie Group, Inc. Investors & Media Amanda Murphy +1 (978) 745-4200 x107